Globe Newswire (Mon, 13-Apr 9:00 AM ET)
Globe Newswire (Wed, 1-Apr 8:45 AM ET)
Globe Newswire (Fri, 27-Mar 8:00 AM ET)
Globe Newswire (Mon, 23-Mar 9:00 AM ET)
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference
Globe Newswire (Tue, 3-Mar 9:05 AM ET)
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
Globe Newswire (Tue, 24-Feb 9:15 AM ET)
Globe Newswire (Fri, 20-Feb 8:50 AM ET)
Globe Newswire (Wed, 11-Feb 8:35 AM ET)
Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026
Globe Newswire (Tue, 3-Feb 9:00 AM ET)
Senti Bio’s SENTI-202 Wins Key FDA RMAT Designation: What 50% Response Rate Means for AML Therapy
Market Chameleon (Tue, 9-Dec 4:54 AM ET)
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
Senti Biosciences Holdings trades on the NASDAQ stock market under the symbol SNTI.
As of April 27, 2026, SNTI stock price declined to $1.06 with 119,070 million shares trading.
SNTI has a beta of 1.98, meaning it tends to be more sensitive to market movements. SNTI has a correlation of 0.07 to the broad based SPY ETF.
SNTI has a market cap of $33.01 million. This is considered a Sub-Micro Cap stock.
Last quarter Senti Biosciences Holdings reported $22,000 in Revenue and -$.53 earnings per share. This fell short of revenue expectation by $-478,000 and missed earnings estimates by -$.07.
In the last 3 years, SNTI traded as high as $16.94 and as low as $.77.
The top ETF exchange traded funds that SNTI belongs to (by Net Assets): VTI, VXF, IWC.
SNTI has underperformed the market in the last year with a return of -78.8%, while the SPY ETF gained +31.2%. In the last 3 month period, SNTI fell short of the market, returning 0.0%, while SPY returned +3.1%. However, in the most recent 2 weeks SNTI has outperformed the stock market by returning +17.6%, while SPY returned +4.2%.
SNTI support price is $1.03 and resistance is $1.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SNTI shares will trade within this expected range on the day.
